hepatic Encephalopathy Ppt
-
Upload
riko-djong -
Category
Documents
-
view
256 -
download
7
Transcript of hepatic Encephalopathy Ppt
-
8/15/2019 hepatic Encephalopathy Ppt
1/69
-
8/15/2019 hepatic Encephalopathy Ppt
2/69
ByProf Dr. Elsaid galal Elbadrawy
Tropical MedicineHepatogastroentrology
Faculty of medicine
Zagazig universiy
-
8/15/2019 hepatic Encephalopathy Ppt
3/69
Hepatic encephalopathy (HE)
describes all the neurosychatric
symptoms occurring in patients
with acute or chronic liver disease
in the absence of other neurologic
disorders
-
8/15/2019 hepatic Encephalopathy Ppt
4/69
PrevalenceThe prevalence of HE depends on
the diagnostic methods used
It can be found in up to 50 to 70%
of cirrhotic patients if
psychometric defects are includedin the diagnostic definition of HE
-
8/15/2019 hepatic Encephalopathy Ppt
5/69
The occurrence of hepatic encephalopathy is onlypossible under the following conditions:
1- Serious acute or chronic liver disease
in which the detoxification function is restricted
2- Functional or anatomic portosystemic collateral circulation must exist through whichthe non-toxified portal blood bypasses the liver,so that toxic substances reach the brain
-
8/15/2019 hepatic Encephalopathy Ppt
6/69
Classification
Associated with acute liver faliureType A:
Portal-systemic bypass withoutintrinsic hepato-cellular disease.
Type B:
Cirrhosis and portal hypertensionwith portal-systemic shunts.
Type C:
The World Congress of Gastroenterology’in 2002 classified hepatic encephalopathy:
-
8/15/2019 hepatic Encephalopathy Ppt
7/69
Type C can fur ther divided into:1-Episodic HE.
Precipitated
Spontaneous
Recurrent encephalopathy
2-Persistent HE.
Mild
SevereTreatment-dependent persistent HE
3-Minimal HE.
-
8/15/2019 hepatic Encephalopathy Ppt
8/69
Many factors have been implicated in
the pathogenesis of HE, but it is the‘multiple -hi t hypothesis’ that appears
most important.
Pathogenes is
-
8/15/2019 hepatic Encephalopathy Ppt
9/69
I) Neurotoxins
1-Ammonia hypothesis:Production:-Small intestine: catabolism of glutamine
-Large intestine: microbial breakdown of protein,amino acids, urea.
-In peripheral tissues (esp. skeletal muscle)
Detoxification:-Liver: (synthesis of urea, glutamine)-Skeletal muscle: alternative target for ammonia
detoxification
-
8/15/2019 hepatic Encephalopathy Ppt
10/69
Ammonia and urea metabolism
-
8/15/2019 hepatic Encephalopathy Ppt
11/69
Role of skeletal muscle in ammonia metabolism inpatients with liver failure
-
8/15/2019 hepatic Encephalopathy Ppt
12/69
-
8/15/2019 hepatic Encephalopathy Ppt
13/69
Extent of hyperammonemia and hepatic
encephalopathy depend on: 1- Nitrogenous intestinal content
2- Change in the intestinal flora
3- Degree of liver dysfunction
4- Extent of portocaval collateral
5- Muscle wasting6- Enzyme defect in urea synthesis
-
8/15/2019 hepatic Encephalopathy Ppt
14/69
Ammonia and glutamate – glutamine cycle
Ammonia affects a number of neurotransmitterthrough its products of metabolism (e.g.glutamate & glutamine ).
In the brain, ammonia is normally detoxified
within the astrocytes and eliminated by theamidation of glutamate.
Glutamate is an excitatory neurotransmitter ;
after reacting with post-synaptic receptors, it isconverted within astrocytes to glutamine
-
8/15/2019 hepatic Encephalopathy Ppt
15/69
Glutamine is neuronally inactive , it modifiesastrocyte signaling and action of glutamate.
In hepatic encephalopathy:1- cerebral glutamine are increased2- cerebral glutamate decreased3- glutamate re-uptake mechanisms are abnormal4- glutamate-binding sites on post-synaptic
neurones are down-regulated.
Increased glutamine in astrocytes → osmoticstress → cellular swelling and cellular change,termed Alzheimer type 2 astrocytosis
-
8/15/2019 hepatic Encephalopathy Ppt
16/69
-
8/15/2019 hepatic Encephalopathy Ppt
17/69
Astrocyte , nerve cells, synapses
-
8/15/2019 hepatic Encephalopathy Ppt
18/69
Ammonia & glutamate – glutamine cycle
-
8/15/2019 hepatic Encephalopathy Ppt
19/69
Mechanism proposed for ammonia in HE:
1- Alter blood brain barrier.
2- cerebral conc. of excitatory aa glutamine
3- Alter brain energy metabolism.
4- Direct effects on neuronal membranes with
change in neurotransmitter receptors
(hyp o thes i s o f p r im ary g l iop athy)
-
8/15/2019 hepatic Encephalopathy Ppt
20/69
NH3
Intestinal protein/bacteria
Reduced hepsticremoval
Reduced muscle mass
Alter BBB Astrocytedamage
glutamineDirect effects
Exicitatory pathways
Sources and potential role of ammonia
-
8/15/2019 hepatic Encephalopathy Ppt
21/69
2)Other possible Toxins:1- Mercaptans & methionine derivatives
(Synergism Hypoth es is )
2- Phenolic Compounds
3- Short Chain Fatty Acids
- Inhibit various enzymes of urea cycle
- Displacement of tryptophan from its bindingto albumin → ↑ tryptophan
-
8/15/2019 hepatic Encephalopathy Ppt
22/69
II) Neurotransmitters
1-GABA hypothesis ( -Amino butyric Acid):GABA is the principal inhibitory neurotransmitterin brainSynthesis:a- In presynaptic neurones: from glutamic acidb- In intestine: by gut bacteria, enter portal vein
and metabolized by liver.In liver failure or portal systemic shuntingsystemic circulation cross BBB to interactwith supersensitive postsynaptic GABA receptors
-
8/15/2019 hepatic Encephalopathy Ppt
23/69
GABA bind to specific GABA receptor in post-
synaptic membrane. This receptors also bindsbenzodiazepines and barbiturates .
Changes in affinity and denisity of postsynapticreceptors play important role for GABA andother neurotransmitter
The binding of benzdiazipines to GABAreceptors intensifies the effect of GABA
-
8/15/2019 hepatic Encephalopathy Ppt
24/69
2-False Neurotransmitter Hypothesis:
The liver plays an essential part in metabolismof amino acids
In chronic liver disease:1- Aromatic amino acids (AAA)
tyrosine, phenylalanine, tryptophane
2- Branches chain amino acids (BCAA) valine, leucine
-
8/15/2019 hepatic Encephalopathy Ppt
25/69
cerebral tryptophan increase synthesis ofserotonin (depressant of conciousness).
phenylalanine in brain inhibit tyrosine 3-hydroxylase, ( key enzyme for synthesis ofcatecholaminergic neurotransmtter
Tyrosine increase synthesize of tyramine, octapamine which complete with catecholamineneurotransmitters for the same receptor site.
brain dopamine and displacement of dopamineby false neurotransmitter impairment ofdopamingeric neurotransmission.
-
8/15/2019 hepatic Encephalopathy Ppt
26/69
Noradrenaline
L-dopa
Dopamine
Sympathetic transmitter
Tyrosine
Tyramine
Octopamine
Phenylalanine
B phenylethanolamine
Tyrosine
Colon: protein
Intestinal bacterial decarboxylase
Disturbed brain metabolism
True False
-
8/15/2019 hepatic Encephalopathy Ppt
27/69
III) Alteration of Bl. Brain Barrier (BBB)
BBB is a complex physiologic processes bywhich the brain is protected from metabolicchanges in the body.
BBB is located at endoth cells of cerebral capill
Transport depends on:
1- Lipid solubility.2- Mediation by specific carriers
-
8/15/2019 hepatic Encephalopathy Ppt
28/69
In hepatic encephalopathy, there is:
1) Increase in the permeability leading to :a- Brain edema.
b- Brain is exposed to circulating neurotoxin.
c- Loss of neurotransmitter2) Alterations of specific carrier systems
a- Increase transport of neutral amino acid
b- Decrease glucose and basic amino acids
-
8/15/2019 hepatic Encephalopathy Ppt
29/69
IV) Altered Brain Energy Metabolism:
Gloucose is the most important cerebralenergy fuel
In cases of cirrhosis with HE, the glucosemetabolism is disturbed
Hypoglycemia in terminal stages of liverfailure may be a consequence of impairedhepatic gluconeogenesis
-
8/15/2019 hepatic Encephalopathy Ppt
30/69
V-Deficiency of essential substancesCirrhosis lead to deficiency of certain vitamins
minerals and micronutrient
Zinc:
Zinc is a cofactor in urea cycleFound in vesicles of glutaminergic presynapticterminals effecting neurotransmission
Replacement should be considered if the patientis deficient
-
8/15/2019 hepatic Encephalopathy Ppt
31/69
VI) Probiotics Ammonia produced by the gut is from thedeamination of dietary amino acids bybacteria
In malnourished patient, the levels of thedefensive bacteria strains (Bifidobacteriumand Lactobacillus) decline.
Probiotics are thought to exert an effect inHE
-
8/15/2019 hepatic Encephalopathy Ppt
32/69
Mult i fac to r ial m ech anis m of H.E
Encephalopathy
Exitatoryglutamate
Arousal( serotonin)
NH3
Motor/cognitive(Dopamine)
Inhibitory
(GABA)
NH3
Tryptophan
Directneuraltoxin
Falseneurotransmitter
EndogenBZ
-
8/15/2019 hepatic Encephalopathy Ppt
33/69
Precipitating F actors
1- Increased protein load
-Upper GI hemorrhage-Ingestion of large protein meal
2- Decreased excretion of ammonia-Renal failure
-Constipation3- Electrolyte disturbance (e.g. hypokalaemia)4- Dehydration5- Paracentesis6- Creation of portacaval shunts7- Infection (SBP)8- Drugs (e.g. sedatives)9- Superimposed acute liver injury
-
8/15/2019 hepatic Encephalopathy Ppt
34/69
Clinical Manifestation
Patients with hepatic encephalopathycan presents with a variety of clinical
features ranging from subc l in ica l o rmin ima l confusion to l i fe-threat iningc o m a with cerebral edema (often infulminant hepatic faliure)
-
8/15/2019 hepatic Encephalopathy Ppt
35/69
1) Disturbed conciousness
-Hypersomnia.
-Confusion, drowsiness.
-Stuper and coma.
2) Personality Changes-Childness, irritability, euphoria.
-Inappropriate loughing or crying.
3) Intellectual Deterioration:
-
8/15/2019 hepatic Encephalopathy Ppt
36/69
4) Emotional Abnormality -Anxiety or depression.
5) Other Features:a) Speech abnormalities:
-Slow and slurred.
-Monotonous voice.-Dysphasia.
b) Convulsions.
c) Brain stem dysfunction-Hypothermia.-Hyperventillation.-Sweating.
-
8/15/2019 hepatic Encephalopathy Ppt
37/69
Examination:
1 ) Asterixes:-Characteristic but not pathognmonic
-Usually bilateral, but not synchronus
-Unilateral asterixes (rare) (with focal lesions ofthe thalamus and parietal cortex).
2) Hyperreflexia.
3) Extenser planter reflexes.4) Neck stiffness (rarely)
-
8/15/2019 hepatic Encephalopathy Ppt
38/69
Fetor Hepaticus:
Sweet musty odor in the breath.
Usually present in hepatic encephalopathy.
Not correlate with degree or duration of HE Attributed to mercaptans which formed in the
intestine by action of bacteria .
-
8/15/2019 hepatic Encephalopathy Ppt
39/69
Clinical variants1-Sub-clinical H. Encephalopathy
Dif: Patients with chronic liver disease whohave no clinical symptoms of braindysfunction, but perform worse onpyschometric tests
It has high prevalence (30 - 70%)
Psychometric tests show that they performwell in tests of intellect, language, memory but poor in tests requiring visual, motor andconstructional skills.
-
8/15/2019 hepatic Encephalopathy Ppt
40/69
Associated with objective changes by C.T
Diagnosed by psychomotric tests:1- Number connection test
2- Digital symbol test
3- Trail test
4- Block design test.
Reversal of subclinical HE can occur withapplication of therapy
-
8/15/2019 hepatic Encephalopathy Ppt
41/69
-
8/15/2019 hepatic Encephalopathy Ppt
42/69
2-A cu te episo d ic (recu rrent) for m Dif: An acute confusional syndrome with
impaired mental state, neuromuscularabnormalities, fetor hepaticus, hyperventilation.
The symptoms appear abruptly and developover a period of hours to days, with oscillationof severity over time
Asterixis is very characteristic
Relapses are common.
Respond well to treatment
-
8/15/2019 hepatic Encephalopathy Ppt
43/69
3-Fulm in an t liv er fal iure:
The clinical features are essentially the same asthose seen in patients with cirrhosis but
The onset is generally abrupt
Marked hepatic fetor is present at early stageNeuropsychatric picture is more aggressive
Signs of increased intracranial pressure
(bradycardia, hypertension, dilated pupils,decerebrate posturing) may also be seen.
-
8/15/2019 hepatic Encephalopathy Ppt
44/69
4-Chro nic pers is tent enc eph alop athy:
- Rare, irreversible encephalopathic syndromes- Found in patients with extended collateral
circulatory pathways
- Neuropsychatric disorder dominate the picture- Picture of liver disease may be equivocal- The most frequent features are:
1- Progressive paraplegia2- Damage to basal ganglia & cerebellar system.3- Focal cerebral symptoms (Epilepsy, dementia)
-
8/15/2019 hepatic Encephalopathy Ppt
45/69
Grades of hepatic encephalopathy
Euphoria or depression, mild confusion,monotonous voice and/or sleep cycledisorders. Asterixis +
Grade I.
Lethargy and/or confusion.Asterixis,
Grade II.
Severe confusion, incoherent language,semi-stupor but awakes with language.
Asterixis
Grade III.
Coma, initially can respond to painfulstimuli.
Grade IV.
-
8/15/2019 hepatic Encephalopathy Ppt
46/69
-Trauma (e.g., subdural hematoma),
-Bleeding, Cerebral infarction-Tumors , Abscess
I-Intracranialles ions
-Meningitis ,Encephalitis,-Subarachnoid hemorrhage
2-Infections
-Anoxia, Uremia ,Ketoacidosis-Hypoglycemia, Electrolyte imbalance-Inborn error of urea cycle, Reye's synd
3 -MetabolicEnceph alopathies
-Alcohol: -Acute intoxication-Withdrawal syndrome- Wernicke's syndrome
-Tranquilizers
4-Toxic
encephalopa thy
5-Neuropsychatr icd isorders
Differential Diagnosis
-
8/15/2019 hepatic Encephalopathy Ppt
47/69
Investigation
1- Clinical Tests (Psychometric tests):2- CSF exam: Glutamic acid and glutamine3- Ammonia:
Raised but not correlate with degree of enceph.
4- Electroencephalography (EEG):Sensitive means of detecting hepatic encephalopathy. Not specific to hepatic encephalopathy.
5- Evoked Potentials:
6- C.T Brain:7- I C P Monitoring8- Myelogram:
-
8/15/2019 hepatic Encephalopathy Ppt
48/69
9-Other investigations:To define cause and precepitating factors
Liver function tests. Bl. Glucose. Serum electrolyte Bl. Urea nitrogen. S. creatinine. Arterial blood gases.
Cultures: blood, urine, sputum. Blood ethanol level.
S. and urine drug screen .
-
8/15/2019 hepatic Encephalopathy Ppt
49/69
Pathology
1-Acute encephalopathy:Cerebral edema are found in 25-50%
2-Chronic encephalopathy:
-Hypertrophy and hyperplasia of astrcoytes-Astrocytes are swollen (Alzhemer's type II cells)
3-Acquired Hepatocerebral degeneration :
-Irreversible degenerative changes in CNS-Diffuse necrosis in cortex-Demylination in spinal cord.
-
8/15/2019 hepatic Encephalopathy Ppt
50/69
PrognosisThe presence of HE is a serious prognosticdevelopment in liver diseases
In ALF , it defines the disease and theprognosis is generally very bad .
In cirrhosis , the 1 year survival rate after anyepisode of encephalopathy is only 40%
Encephalopathy indicate liver failure , andshould prompt consideration of livertransplantation
-
8/15/2019 hepatic Encephalopathy Ppt
51/69
TREATMENT
1-Tr eatment of Precipitating F actors: Constipation
Electrolyte and acid-base imbalance Infection (SBP)
Gastrointestinal bleeding
Portal-systemic shunts .
-
8/15/2019 hepatic Encephalopathy Ppt
52/69
2-Tr eatment of Complications of Acute
L iver failure: 1-Monitored cardiovascular , respiration and
metabolic parameters
2-Prophylactic antibiotic3-Intracranial pressure monitoring.
If above 25 mm Hg Mannitol, Thiopental
3-Orthotropic liver Transplantation
-
8/15/2019 hepatic Encephalopathy Ppt
53/69
Specif ic Treatment
1- Treatment based on ammonia hypothesis
2- Treatment based on false neurotransmitter
3- Treatment based on GABA hypothesis
4- Adjuvant therapy
4- Probiotics
-
8/15/2019 hepatic Encephalopathy Ppt
54/69
I-Treatm en t b ased o n am m o niahypo thes i s
Ammniogenic
substrate
Intestinalammonia
production
Metabolicammonia
fixation
1- Dietary protein
2- Enema
1- Antibiotics2- Lactulose
1-Ornithine aspart2-Benzoate &
Phenylacetate
-
8/15/2019 hepatic Encephalopathy Ppt
55/69
1- Decrease of Ammoniagenic Substrates.
a) Reduce dietary protein :Subclinical HE 40 gm/day
Grade 1 or 2 30 gm/day
Acute and severe attack (Grade 3 or 4)-Withdrowal all dietary protein
- Calories intake is maintained at 2000 cal
/day or above either oral or IV.
-
8/15/2019 hepatic Encephalopathy Ppt
56/69
Dur ing Reco very :
Protein intake is increased by 10 gm/day
every 3 rd day until normal intake (60-80 gm/d)In Chr on ic Cases:
Perminant protein restriction
The limit of tolerance is 40-60 gm/day.
Vegitable Pro te in:
Tolerated better than animal protein.
Less ammoniagnic
More laxative due to their high fiber content.
-
8/15/2019 hepatic Encephalopathy Ppt
57/69
Calor ie intake:
1,800-2,500 (cal/d) is guaranteed by theadequate adminstration of fats (70-140 g) andCHO (280-325g)
Insulin (cirrhotic patients show insulinresistance)
Vitam ins :
Daily intake of multivitamins , trace element ,minerals , zinc is recommended
-
8/15/2019 hepatic Encephalopathy Ppt
58/69
2) Enema:In acute and severe coma especially inhighly constipated patients or in cases ofmassive GIT bleeding
The volume used should be at least 1000 ml
300 ml lactulose with 700 ml water areefficacious
-
8/15/2019 hepatic Encephalopathy Ppt
59/69
(2) Inhibition of Intestinal Ammonia Production:
1-Anhibiotics:1- Neomycin
Alter gut flora ( E-coli , urease producing org.)
Impair absorption of ammonia
Inhibit uptake of glutamic acid by mucosal cells
Dose: 1-2 gm / 6h oral or rectally
Only used for short-term therapy (toxicity)
-
8/15/2019 hepatic Encephalopathy Ppt
60/69
2-Metronidazole. Active aginst bacteroids and other anerobes
Effective as neomycin.Dose: 200 mg 4 times daily.should not be used long-term ( CNS toxicity)
3-VancomycinReduces bacteroidsSuccessively used in patients with lactulose
therapy faliureDose: 4 X 0.5 gm/day
-
8/15/2019 hepatic Encephalopathy Ppt
61/69
2-Lactulose-Non absorbable, synthetic disaccharide. Mode of action: 1-Osmotic laxative.2-Promotes lactobacilli growth increased lactic,
acetic, and formic acids decreased colonicPH inhibits growth of urease-producingbacteria especially E-coli.
3-Traps luminal ammonia and its absorption.4- Increase diffusion of ammonia from themucosal blood into the gut.
-
8/15/2019 hepatic Encephalopathy Ppt
62/69
Lactitol:
Similar to lactulose in action.More palatable (Less sweet )
Causes less diarrhea and flatulence .
Lactose:Effective substitute for lactulose in patients
who are known to be lactase deficient.
-
8/15/2019 hepatic Encephalopathy Ppt
63/69
3-Stimulation of Metabolic Ammonia Fixation:a)Ornithine -keto glutarate or ornithine
aspartate-Ornithine is a substrate of urea synthesis
-Aspartate, ornithine reinforce glutamine
synthesis which serve to detoxify ammonia-They improves HE in cirrhotic patients
b)Benzoate and Phenylacetate:
-Successfully used in treatment of congenitalenzymatic defect of urea synthesis
-
8/15/2019 hepatic Encephalopathy Ppt
64/69
II-Treatm ent b ased o n th e false-
neuro t rans m i t ter Hypo thes i s
1-Branched-Chain Amino Acids:
May be of value for long term treatment of HE.
Provides safe and well-tolerated source ofnutrition in patients with cirrhosis
BCAAs treatment leads to:-
1- Improvement in nitrogen balance.
2- Less protein catabolism.
3- Enhanced protein synthesis.
-
8/15/2019 hepatic Encephalopathy Ppt
65/69
2-L-Dopa and Bromocryptine:
Decreased dopaminergic neurotransmission is
a component of false neurotransmitter theory.a) Levo -do pa:
A precursor of the neurotransmettersnorepinephrine and dopamine
b) Bromocreptine :
-Specific dopamine receptor agonist
-Give improvement in chronic portosystemicencephalopathy
-
8/15/2019 hepatic Encephalopathy Ppt
66/69
III- Treatmen t B ased o n th e GAB A
Hypo thes i s " Flum azeni l
Benzodiazepine-receptor antagonist.
induce transient improvement in 70% ofpatients with HE
Dose: 0.2- 0.3 mg IV bolus, followed by5mg/h as IV infusion
-
8/15/2019 hepatic Encephalopathy Ppt
67/69
IV-A d juv an t therap y
1-PiracetamNootropic substance
improve typical electrical brain activities
2-L-carnitineMarkedly reduce hyperammonaemia
Improve the clinical symptoms of HE in cirrhoticpatients
-
8/15/2019 hepatic Encephalopathy Ppt
68/69
V- Prob iot ics They have multiple beneficial effects in treatment
of minimal HE by :1- Decrease total ammonia in portal blood by:
a) ↓ bacterial urease activity
b) ↓ ammonia absorption by decreasing pHc) ↓ intestinal permeabilityd) improving nutritional status of gut epithelium.
2- Decrease inflammation and oxidative stress inhepatocyte → ↑ hepatic clearance of ammonia
3- Decreasing uptake of other toxins.
-
8/15/2019 hepatic Encephalopathy Ppt
69/69